Portola Pharmaceuticals (NASDAQ:PTLA) Upgraded by BidaskClub to “Hold”
Several other brokerages have also recently issued reports on PTLA. Morgan Stanley set a $37.00 price objective on shares of Portola Pharmaceuticals and gave the stock a hold rating in a research note on Friday, August 9th. Credit Suisse Group reaffirmed a neutral rating and issued a $35.00 price objective on shares of Portola Pharmaceuticals in a research note on Monday, August 5th. Cowen reaffirmed a buy rating and issued a $45.00 price objective on shares of Portola Pharmaceuticals in a research note on Thursday, August 8th. ValuEngine cut shares of Portola Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, May 1st. Finally, Zacks Investment Research cut shares of Portola Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, August 13th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $41.43.
Shares of PTLA opened at $28.89 on Friday. The firm’s 50 day moving average is $27.30 and its 200-day moving average is $30.30. The stock has a market capitalization of $2.08 billion, a P/E ratio of -5.77 and a beta of 2.18. The company has a debt-to-equity ratio of 453.47, a current ratio of 3.63 and a quick ratio of 3.61. Portola Pharmaceuticals has a 12-month low of $14.81 and a 12-month high of $37.95.
In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the director now directly owns 18,194 shares in the company, valued at $545,820. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.50% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio boosted its holdings in shares of Portola Pharmaceuticals by 1.3% in the first quarter. Strs Ohio now owns 45,600 shares of the biopharmaceutical company’s stock worth $1,582,000 after buying an additional 600 shares during the period. Advisor Group Inc. boosted its holdings in shares of Portola Pharmaceuticals by 7.9% in the second quarter. Advisor Group Inc. now owns 9,302 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 681 shares during the period. Icon Wealth Partners LLC acquired a new stake in shares of Portola Pharmaceuticals during the first quarter worth approximately $26,000. Empire Life Investments Inc. boosted its holdings in shares of Portola Pharmaceuticals by 1.6% during the second quarter. Empire Life Investments Inc. now owns 59,159 shares of the biopharmaceutical company’s stock worth $1,604,000 after purchasing an additional 940 shares during the period. Finally, FTB Advisors Inc. acquired a new stake in shares of Portola Pharmaceuticals during the first quarter worth approximately $33,000.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Featured Article: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.